Gliclazide treatment lowers serum ICAM-1 levels in poorly controlled type 2 diabetic patients.
Papanas N, Tziakas D, Chalikias G, Floros D, Trypsianis G, Papadopoulou E, Kortsaris A, Symeonidis G, Souliou E, Maltezos E, Hatseras D.
Papanas N, et al. Among authors: symeonidis g.
Diabetes Metab. 2006 Sep;32(4):344-9. doi: 10.1016/s1262-3636(07)70289-6.
Diabetes Metab. 2006.
PMID: 16977262
Clinical Trial.